BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bayer HealthCare (BAY) to Present Data on Oncology Pipeline at the American Association for Cancer Research 102nd Annual Meeting


4/1/2011 9:27:25 AM

Berlin, April 1, 2011 – Bayer HealthCare today announced that the company will present preclinical data that introduces investigational compounds for both therapy and imaging in its early oncology pipeline with unique and novel mechanisms at the American Association for Cancer Research (AACR) 102nd Annual Meeting, April 2-6, 2011, in Orlando, FL. The AACR meeting highlights the latest discoveries and developments in oncology research.

Two of these compounds are BAY 87-2243, an inhibitor of hypoxia-inducible HIF-1a activation, and MT112/BAY 2010112, a BiTE? antibody, being developed in partnership with Micromet, Inc. Data will also be presented on two compounds, BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC) developed in collaboration with ImmunoGen Inc., and BAY 79-4620, a CA9-targeted ADC developed in collaboration with Seattle Genetics, Inc. These compounds are being developed to target antigens, mesothelin and carbonic anhydrase 9 (CA9), both of which are selectively expressed on certain tumors.

"The breadth and depth of research data being presented at this conference shows that Bayer is committed to researching and developing a wide variety of compounds and pathways in the hopes of discovering new, innovative ways to fight various types of cancer,” said Dr. Karl Ziegelbauer, Head of Therapeutic Research Group Oncology, Bayer HealthCare. “We are excited to present this new research, which includes data on several of the latest compounds to enter clinical testing, as well as on those being evaluated in our companion diagnostics program, which may help us to identify patients who may benefit most from our medicines.”

An oral presentation providing an overview on the anti-frizzled antibody 18R5 that targets cancer stem cells will be given by OncoMed Pharmaceuticals, Inc. This compound is part of the global strategic alliance signed in June 2010 between OncoMed and Bayer to discover, develop and commercialize innovative anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

Additionally, preclinical data will be presented on regorafenib (BAY 73-4506), an oral multi-kinase inhibitor, and Alpharadin (radium-223 chloride), an alpha-pharmaceutical, which are both currently being evaluated in separate Phase III clinical trials. In September 2009, Bayer signed an agreement with Algeta ASA for the development and commercialization of Alpharadin.

Data on two novel PET tracers BAY 86-4367, a F-18 labeled bombesin analog, and BAY 94-9392, a derivative of L-glutamate for improved diagnosis and staging of certain tumor types will be shown.

A total of 12 abstracts evaluating investigational compounds in Bayer’s pipeline will be presented at AACR. The abstracts are as follows:

Oral Presentations

- Targeting cancer stem cells by a novel anti-frizzled antibody inhibits pancreatic tumor growth and induces differentiation

- Abstract 973, Stem Cells in Cancer Biology and Therapy 1 Minisymposium

- Sunday, April 3, 2011, 3:35-3:50 p.m., West Hall F5, Orange County Convention Center

- BAY 94-9392 - A new derivative of L-glutamate for tumor specific PET imaging

- Abstract 2800, Metabolic Regulation and Cancer Minisymposium

- Monday, April 4, 2011, 3:35-3:50 p.m., West Hall F1/F2, Orange County Convention Center

Poster Presentations

- F-FAZA-PET as a pharmacodynamic biomarker of anti-tumor activity for the novel HIF-1a pathway inhibitor BAY 87-2243 in preclinical tumor models

- Abstract LB-147, Late-Breaking Research: Cellular and Molecular Biology 2 Poster Session

- Monday, April 4, 2011, 8:00 a.m.-12:00 p.m., Exhibit Hall A4-C

- Identification of BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models

- Abstract 1754, Targeting Cell Surface Proteins/Apoptosis Poster Session

- Monday, April 4, 2011, 8:00 a.m.-12:00 p.m., Exhibit Hall A4-C

- Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo

- Abstract 4139, Radiation Response Modifiers: Preclinical and Clinical Studies Poster Session

- Monday, April 4, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

- In vivo efficacy of the carbonic anhydrase IX (CA9)-targeted antibody-drug conjugate BAY 79-4620 is superior to that of microtubule inhibitors in preclinical models of NSCLC, gastric and colorectal cancer

- Abstract 3614, Novel Biologics and Antibody-Drug Conjugates Poster Session

- Tuesday, April 5, 2011, 8:00 a.m.-12:00 p.m., Exhibit Hall A4-C

- Molecular mechanisms by which BAY 80-6946 induces apoptosis in breast tumor cells as single agent or in combination

- Abstract 3833, Cancer Cell Signaling 7 Poster Session

- Tuesday, April 5, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

- BAY 87-2243 targets hypoxia-induced activation and stabilization of HIF-1a: A novel approach to overcome resistance mechanisms in cancer therapy

- Abstract 4509, Targeted Agents Poster Session

- Tuesday, April 5, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

- BAY 87-2243, an inhibitor of HIF-1a activation and stabilization, showed promising anti-tumor efficacy either as monotherapy or in combination with anti-VEGF and chemotherapy agents in preclinical tumor models

- Abstract 4503, Targeted Agents Poster Session

- Tuesday, April 5, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

- Regorafenib (BAY 73-4506): A broad spectrum tumor deactivator with high combinability potential and antimetastasis activity

- Abstract 4262, Angiogenesis Inhibitors 2 Poster Session

- Tuesday, April 5, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

- Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer

- Abstract 4561, Cancer-targeting Antibodies Poster Session

- Tuesday, April 5, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

- Diagnostic performance of the F-18 labeled bombesin analog BAY 86-4367 in patients with primary prostate cancer

- Abstract 2664, Functional Imaging and Noninvasive Diagnostics Poster Session

- Tuesday, April 5, 2011, 1:00-5:00 p.m., Exhibit Hall A4-C

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES